Rabeprazole (Rabeprazole SPEC)
Rabeprazole
Specpharm (Pty) Ltd
Registration
- Applicant
- Specpharm (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Rabeprazole 10 SPEC Each tablet contains 10,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 9,42 mg | 10 | 49095549/11.4.3/0955 | Registered | Not determined | None |
| Rabeprazole 20 SPEC Each tablet contains 20,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 18,85 mg | 20 | 49095649/11.4.3/0956 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Rabeprazole
- except when intended for the temporary short term relief of heartburn and hyperacidity, subject to-
- maximum daily dose of 10 milligrams;
- maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 7702 to 7707
S2: Rabeprazole
- when intended for the temporary short term relief of heartburn and hyperacidity, subject to-
- maximum daily dose of 10 milligrams;
- maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 2619 to 2623
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
Drag to rotate. Structure from PubChem CID 5029.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.